HK1052368A1 - 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 - Google Patents

具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 Download PDF

Info

Publication number
HK1052368A1
HK1052368A1 HK03104476.2A HK03104476A HK1052368A1 HK 1052368 A1 HK1052368 A1 HK 1052368A1 HK 03104476 A HK03104476 A HK 03104476A HK 1052368 A1 HK1052368 A1 HK 1052368A1
Authority
HK
Hong Kong
Prior art keywords
nucleic acid
processing component
acid construct
antigenic polypeptide
construct encoding
Prior art date
Application number
HK03104476.2A
Other languages
English (en)
Chinese (zh)
Inventor
Li Fan
Andrew Anderson David
Francis John Purcell Damian
Original Assignee
Macfarlane Burnet Institute For Medical Research And Public Health Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macfarlane Burnet Institute For Medical Research And Public Health Limited filed Critical Macfarlane Burnet Institute For Medical Research And Public Health Limited
Publication of HK1052368A1 publication Critical patent/HK1052368A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HK03104476.2A 2000-03-31 2001-03-30 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構 HK1052368A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ6616A AUPQ661600A0 (en) 2000-03-31 2000-03-31 A nucleic acid construct and methods related thereto
AUPQ661600 2000-03-31
PCT/AU2001/000353 WO2001073078A1 (en) 2000-03-31 2001-03-30 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide

Publications (1)

Publication Number Publication Date
HK1052368A1 true HK1052368A1 (zh) 2003-09-11

Family

ID=3820712

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104476.2A HK1052368A1 (zh) 2000-03-31 2001-03-30 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構

Country Status (14)

Country Link
US (1) US7341723B2 (enExample)
EP (1) EP1274851B1 (enExample)
JP (1) JP2003528614A (enExample)
KR (1) KR100768051B1 (enExample)
CN (1) CN1426472A (enExample)
AT (1) ATE430804T1 (enExample)
AU (1) AUPQ661600A0 (enExample)
CA (1) CA2407036A1 (enExample)
DE (1) DE60138612D1 (enExample)
HK (1) HK1052368A1 (enExample)
MX (1) MXPA02009437A (enExample)
NZ (1) NZ521758A (enExample)
WO (1) WO2001073078A1 (enExample)
ZA (1) ZA200207769B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004761A2 (en) 2002-07-05 2004-01-15 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
KR100641810B1 (ko) * 2004-04-23 2006-11-06 주식회사 포스코건설 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주
US8906863B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
EP2400982B1 (en) * 2009-02-27 2016-05-11 The Regents of The University of California Multiple antigen delivery system using hepatitis e virus-like particle
US8906862B2 (en) 2009-02-27 2014-12-09 The Regents Of The University Of California Multiple antigen delivery system using hepatitis E virus-like particle

Also Published As

Publication number Publication date
US7341723B2 (en) 2008-03-11
EP1274851B1 (en) 2009-05-06
EP1274851A1 (en) 2003-01-15
WO2001073078A1 (en) 2001-10-04
EP1274851A4 (en) 2004-12-08
DE60138612D1 (de) 2009-06-18
MXPA02009437A (es) 2006-05-25
KR100768051B1 (ko) 2007-10-18
ATE430804T1 (de) 2009-05-15
KR20030015223A (ko) 2003-02-20
AUPQ661600A0 (en) 2000-05-04
CA2407036A1 (en) 2001-10-04
CN1426472A (zh) 2003-06-25
US20030158138A1 (en) 2003-08-21
ZA200207769B (en) 2004-02-10
JP2003528614A (ja) 2003-09-30
NZ521758A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
WO2001098333A3 (en) Modification of hepatitis b core antigen
DK0414374T3 (da) Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DK1829551T3 (da) Modificeret varmchokprotein-antigenpeptid-kompleks
WO1999057289A3 (en) INHIBIN-HBc FUSION PROTEIN
ATE325882T1 (de) Polypeptide, die mit alfalfamosaikviralen oder ilarviralen kapsiden fusioniert sind
WO2004004761A3 (en) Adjuvant viral particle
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
WO2002060921A3 (en) Enhancement of immune response to vaccine by interferon alpha
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
WO1996038474A3 (en) Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide
HK1052368A1 (zh) 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
WO2006020480A3 (en) Adenoviral vector compositions
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
DK1506222T3 (da) Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
EP1035133A3 (en) Fusion proteins comprising carriers that can induce a dual immune response
AU5573196A (en) A pluripotent vaccine against enveloped viruses
FI923020A0 (fi) Inte a inte b-sekvenser.
WO2001027282A8 (en) Plant virus particles with exogenous internal eitopes
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
AU7546500A (en) Designing immunogens